We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Under the terms of the agreement, the methods that will come out of this partnership will be made available to other domestic generics manufacturers. Read More
To stretch the available doses, the FDA issued an emergency authorization that allows for a one-fifth dose to be administered beneath the top layer of the skin. Read More
West Chester, Pa.-based Verrica Pharmaceuticals drew a second Complete Response Letter (CRL) from the FDA rejecting the company’s New Drug Application (NDA) for its investigational drug VP-102 to treat patients with the viral skin disease molluscum contagiosum. Read More
RSS
